发布求助
文献互助 智能选刊 最新文献

Blood Cancer Discovery最新文献

筛选
英文 中文
High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study. 大剂量甲氨蝶呤、依鲁替尼和替莫唑胺治疗新诊断的原发性中枢神经系统淋巴瘤：一项多中心、前瞻性ii期研究
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-24-0156
Yan Gao, Liqin Ping, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Mingyao Lai, Linbo Cai, Bing Bai, Cheng Huang, Haoqing Chen, Xiaoyu Hong, Xiaoxiao Wang, Huiqiang Huang
{"title":"High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study.","authors":"Yan Gao, Liqin Ping, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Mingyao Lai, Linbo Cai, Bing Bai, Cheng Huang, Haoqing Chen, Xiaoyu Hong, Xiaoxiao Wang, Huiqiang Huang","doi":"10.1158/2643-3230.BCD-24-0156","DOIUrl":"10.1158/2643-3230.BCD-24-0156","url":null,"abstract":"<p><strong>Significance: </strong>We report promising efficacy and good tolerability of Bruton tyrosine kinase (BTK) inhibitor ibrutinib in treatment of newly diagnosed PCNSL. Additionally, we explored the contribution of ctDNA profiling to predictive potential in this prospective study. The consistency of ctDNA clearance from CSF/plasma was associated with more sustained treatment response and survival.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"191-202"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy. 超越试验和错误：一个数学模型争论DLBCL的异质性，以优化联合治疗。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-25-0071
Jordan S Goldstein, Nick A Phillips, Ash A Alizadeh
{"title":"Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy.","authors":"Jordan S Goldstein, Nick A Phillips, Ash A Alizadeh","doi":"10.1158/2643-3230.BCD-25-0071","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-25-0071","url":null,"abstract":"<p><p>In this issue of Blood Cancer Discovery, Pomeroy and Palmer present a new mathematical model, incorporating both inter- and intra-patient heterogeneity, to accurately predict outcomes for first-line combination therapies in diffuse large B-cell lymphoma. Their quantitative framework opens a range of possibilities for optimizing trial design and lymphoma therapy with potential to expedite clinical development. See related article by Pomeroy and Palmer, p. 254.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":"6 3","pages":"153-156"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unleashing the Full Potential of Metabolic Interventions in T-ALL. 释放T-ALL代谢干预的全部潜力。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-25-0012
Victoria da Silva-Diz, Daniel Herranz
{"title":"Unleashing the Full Potential of Metabolic Interventions in T-ALL.","authors":"Victoria da Silva-Diz, Daniel Herranz","doi":"10.1158/2643-3230.BCD-25-0012","DOIUrl":"10.1158/2643-3230.BCD-25-0012","url":null,"abstract":"<p><p>Drugs targeting metabolism have been effectively used in patients with T-cell acute lymphoblastic leukemia (T-ALL) for decades; still, the full therapeutic potential of targeting metabolism has not been completely exploited yet. Here, we highlight the critical need for metabolic biomarkers to advance precision medicine in T-ALL, explore the identification of novel metabolic vulnerabilities, and discuss the potential of targeted therapies and dietary interventions to optimize treatment outcomes.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"163-167"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma. Brexucabtagene自体甲醇与异基因造血细胞移植治疗复发难治性套细胞淋巴瘤。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-24-0178
Nora Liebers, Ariane Boumendil, Hervé Finel, Dominic Edelmann, Guido Kobbe, Ben-Niklas Baermann, Yasmina Serroukh, Didier Blaise, Dietrich Wilhelm Beelen, Carlos Solano, Maija Itälä-Remes, Tom van Meerten, Goda Choi, Susanne Anna Christine Schmidt, Nicolaus Kröger, Jenny Byrne, Jean-Jacques Tudesq, Anna Ossami Saidy, Ana Nunes, Rubina Siddiqi, Elande Baro, Dan Zheng, Ioana Kloos, Peter Dreger, Anna Sureda, Bertram Glass, Sascha Dietrich
{"title":"Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma.","authors":"Nora Liebers, Ariane Boumendil, Hervé Finel, Dominic Edelmann, Guido Kobbe, Ben-Niklas Baermann, Yasmina Serroukh, Didier Blaise, Dietrich Wilhelm Beelen, Carlos Solano, Maija Itälä-Remes, Tom van Meerten, Goda Choi, Susanne Anna Christine Schmidt, Nicolaus Kröger, Jenny Byrne, Jean-Jacques Tudesq, Anna Ossami Saidy, Ana Nunes, Rubina Siddiqi, Elande Baro, Dan Zheng, Ioana Kloos, Peter Dreger, Anna Sureda, Bertram Glass, Sascha Dietrich","doi":"10.1158/2643-3230.BCD-24-0178","DOIUrl":"10.1158/2643-3230.BCD-24-0178","url":null,"abstract":"<p><strong>Significance: </strong>Patients aged ≥50 years with r/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk-benefit evaluation is essential to guide optimal treatment decisions.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"182-190"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Escape of Acute Myeloid Leukemia after Transplantation. 急性髓系白血病移植后的免疫逃逸。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-24-0063
Nguyen Huong Jenny Giang Ho, Nana Talvard-Balland, Natalie Köhler, Robert Zeiser
{"title":"Immune Escape of Acute Myeloid Leukemia after Transplantation.","authors":"Nguyen Huong Jenny Giang Ho, Nana Talvard-Balland, Natalie Köhler, Robert Zeiser","doi":"10.1158/2643-3230.BCD-24-0063","DOIUrl":"10.1158/2643-3230.BCD-24-0063","url":null,"abstract":"<p><strong>Significance: </strong>We discuss the mechanisms of AML immune evasion including loss or downregulation of MHC class I and II, reduced TRAIL receptor expression, inhibitory metabolite production, inhibitory ligand expression, impaired proinflammatory cytokine production, and AML niche alterations.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"168-181"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One for All and All for One: New Insights into Enhancers Driving MYC Dysregulation. 我为人人，人人为我：对MYC失调增强因子的新见解。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-25-0075
Roger Mulet-Lazaro, Ruud Delwel
{"title":"One for All and All for One: New Insights into Enhancers Driving MYC Dysregulation.","authors":"Roger Mulet-Lazaro, Ruud Delwel","doi":"10.1158/2643-3230.BCD-25-0075","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-25-0075","url":null,"abstract":"<p><p>The role of the proto-oncogene MYC as a driver of lymphoma has been known since the 1980s, but the mechanisms underlying its dysregulation are not completely understood. In this issue of Blood Cancer Discovery, Iyer and colleagues employ a CRISPR interference screen targeted at open chromatin regions to unveil enhancers critical for MYC overexpression in lymphoma, including a novel regulatory element in the MYC locus that controls germinal center reentry and is recurrently amplified in diffuse large B-cell lymphomas (germinal center B-cell diffuse large B-cell lymphoma). See related article by Iyer et al., p. 233.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":"6 3","pages":"149-152"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma. myc -完整和myc -重排生发中心b细胞弥漫性大b细胞淋巴瘤的选择性增强子依赖性
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-24-0126
Ashwin R Iyer, Aishwarya Gurumurthy, Shih-Chun A Chu, Rohan Kodgule, Athalee R Aguilar, Travis Saari, Abdullah Ramzan, Jan Rosa, Juhi Gupta, Arvind Emmanuel, Cody N Hall, John S Runge, Anna B Owczarczyk, Jang W Cho, Matthew B Weiss, Rockwell Anyoha, Kristin Sikkink, Savanna Gemus, Charles P Fulco, Anamarija M Perry, Anthony D Schmitt, Jesse M Engreitz, Noah A Brown, Marcin P Cieslik, Russell J H Ryan
{"title":"Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma.","authors":"Ashwin R Iyer, Aishwarya Gurumurthy, Shih-Chun A Chu, Rohan Kodgule, Athalee R Aguilar, Travis Saari, Abdullah Ramzan, Jan Rosa, Juhi Gupta, Arvind Emmanuel, Cody N Hall, John S Runge, Anna B Owczarczyk, Jang W Cho, Matthew B Weiss, Rockwell Anyoha, Kristin Sikkink, Savanna Gemus, Charles P Fulco, Anamarija M Perry, Anthony D Schmitt, Jesse M Engreitz, Noah A Brown, Marcin P Cieslik, Russell J H Ryan","doi":"10.1158/2643-3230.BCD-24-0126","DOIUrl":"10.1158/2643-3230.BCD-24-0126","url":null,"abstract":"<p><strong>Significance: </strong>Aberrant MYC activity defines the most aggressive GCB-DLBCLs. We characterized a mechanism of MYC transcriptional activation via a native enhancer that is active in MYC-intact GCB-DLBCL, establishing fitness-sustaining cis- and trans-regulatory circuitry in GCB-DLBCL models that lack MYC enhancer-hijacking rearrangement. See related commentary by Mulet-Lazaro and Delwel, p. 149.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"233-253"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma. 肿瘤内和患者间异质性模型解释了淋巴瘤根治性联合疗法的临床试验。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-24-0230
Amy E Pomeroy, Adam C Palmer
{"title":"A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma.","authors":"Amy E Pomeroy, Adam C Palmer","doi":"10.1158/2643-3230.BCD-24-0230","DOIUrl":"10.1158/2643-3230.BCD-24-0230","url":null,"abstract":"<p><strong>Significance: </strong>A new model of intratumor and interpatient heterogeneity in response to drug combinations explains and predicts the results of clinical trials of curative-intent treatments for DLBCL. This model can be used to understand and inform optimal design of curative drug combinations and clinical trials. See related commentary by Goldstein et al., p. 153.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"254-269"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy. 急性髓系白血病对过继t细胞治疗反应性的悖论。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-25-0017
Terry J Fry
{"title":"The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy.","authors":"Terry J Fry","doi":"10.1158/2643-3230.BCD-25-0017","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-25-0017","url":null,"abstract":"<p><p>Since the recognition of the allogeneic graft-versus-leukemia effect, acute myeloid leukemia (AML) has been identified as a T cell-targetable malignancy, but success with modern forms of immunotherapy has been slower than anticipated. In this issue, we discuss the biological barriers to the treatment of AML with T-cell therapy revealed by recent reports, including mechanistic insights into AML resistance to T cell-mediated killing by Tin and colleagues. See related article by Tin et al., p. 217.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":"6 3","pages":"157-158"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity. SOCS1 可保护急性髓性白血病免受异体 T 细胞介导的细胞毒性的影响。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-05-05 DOI: 10.1158/2643-3230.BCD-24-0140
Enoch Tin, Sergio Rutella, Ismat Khatri, Yoosu Na, Yongran Yan, Neil MacLean, Jayakumar Vadakekolathu, Mark D Minden, Aaron D Schimmer, JongBok Lee, Li Zhang
{"title":"SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity.","authors":"Enoch Tin, Sergio Rutella, Ismat Khatri, Yoosu Na, Yongran Yan, Neil MacLean, Jayakumar Vadakekolathu, Mark D Minden, Aaron D Schimmer, JongBok Lee, Li Zhang","doi":"10.1158/2643-3230.BCD-24-0140","DOIUrl":"10.1158/2643-3230.BCD-24-0140","url":null,"abstract":"<p><strong>Significance: </strong>Our investigation of the SOCS1 pathway in AML and T-cell interactions provides insights into potential mechanisms of resistance of AML to allogeneic hematopoietic stem cell transplantation and demonstrates the potential of targeting SOCS1 and its downstream mediators to enhance antileukemic T-cell activity. See related commentary by Fry, p. 157.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"217-232"},"PeriodicalIF":11.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信